All Oncology News

Selinexor/Ruxolitinib Combo Elicits Sustained Spleen Responses, Improves Symptoms in Myelofibrosis

April 21st 2023

The combination of selinexor at 60 mg and ruxolitinib induced rapid and durable spleen responses and improved symptoms at weeks 12 and 24 in patients with treatment-naïve myelofibrosis, according to updated data from the phase 1 XPORT-MF-034 trial.

Batiraxcept Plus Cabozantinib Has Tolerable Safety Profile in Metastatic Clear Cell RCC

April 21st 2023

The combination of batiraxcept and cabozantinib is safe and generated early evidence of efficacy in pretreated patients with advanced or metastatic clear cell renal cell carcinoma.

Fox Chase Cancer Center Clinical Director Wins Oncology Nursing Society’s Excellence in Cancer Nursing Management Award

April 21st 2023

Erin Longstreth-Papsun, RN, MSN, OCN, NEA-BC, clinical director of Ambulatory Satellite Clinics and Radiation Oncology Nursing at Fox Chase Cancer Center, was recently awarded the Excellence in Cancer Nursing Management Award by the Oncology Nursing Society (ONS).

Tislelizumab Plus Chemotherapy Meets OS End Point in Advanced Gastric/GEJ Adenocarcinoma

April 21st 2023

The combination of tislelizumab plus chemotherapy elicited a statistically significant and clinically meaningful improvement in overall survival compared with chemotherapy plus placebo in patients with advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

O’Shaughnessy Showcases Highlights in Breast Cancer Guiding 2023 IBC Congresses

April 21st 2023

Joyce A. O’Shaughnessy, MD, highlights multidisciplinary approaches including discussions on tumor boards, and discusses how to better assist patients with accessing care, and notable advances in the field particularly with the HER2 classification.

FDA Extends Review for Quizartinib in Newly Diagnosed FLT3-ITD+ AML

April 21st 2023

The FDA has extended the review period for a new drug application for quizartinib in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and as continuation monotherapy following consolidation, for the treatment of newly diagnosed adult patients with FLT3-ITD–positive acute myeloid leukemia.

Novel Methylation-Based Platform Shows Promise for Multicancer Early Detection

April 21st 2023

A genome-wide methylome enrichment platform demonstrated efficacy in detecting early-stage, low-shedding cancers with limited circulating tumor DNA.

Endoscopic Strategies Broaden the Pancreatic Cancer Diagnostic and Treatment Paradigms

April 20th 2023

In pancreatic cancer, the role of the endoscopist continues to evolve as technologies like endoscopic ultrasound–guided biopsies present clinicians with increasingly accurate information to characterize the tumor microenvironments of individual patients and determine effective targeted therapies.

BASECAMP-1 Aims to Identify Patients Eligible for Treatment With Novel CAR T-Cell Agent

April 20th 2023

Looking to replicate the impressive findings with CAR T-cell therapies observed in patients with hematologic malignancies, investigators have initiated the BASECAMP-1 trial, with the hope of identifying patients with advanced solid tumors who will be suitable candidates for treatment in a subsequent trial evaluating the investigational agent A2B530.

Expanded Genomic and Early-Detection Testing Define Next Level of Precision Oncology Screening and Management

April 20th 2023

Head and Neck, Breast cancer Research Highlights AACR Abstracts

April 20th 2023

University of Cincinnati Cancer Center researchers presented more than a dozen abstracts at the 2023 American Association for Cancer Research Annual Meeting, including findings that could advance treatments for head and neck and breast cancers.

VB10.16 Plus Atezolizumab Generates Positive Survival Data in PD-L1+ Advanced Cervical Cancer

April 20th 2023

The combination of the potentially first-in-class off-the-shelf therapeutic cancer vaccine candidate VB10.16 and atezolizumab elicited a median overall survival greater than 25 months in patients with PD-L1–positive, human papillomavirus 16–positive advanced cervical cancer.

Leaked Data Show Cilta-cel Delivers 74% Reduction in Risk of Progression in Early Relapsed/Refractory Myeloma

April 20th 2023

Leaked data from an abstract scheduled to be presented at the 2023 EHA Hybrid Congress showed that ciltacabtagene autoleucel demonstrated a 74% reduction in the risk of disease progression or death compared with standard therapy in patients with relapsed/refractory multiple myeloma who received 1 to 3 prior lines of therapy.

Oncology Financial Navigator Interventions Provide Benefits to Patients With Hematologic Cancers

April 20th 2023

To evaluate the prevalence of financial toxicity and observe the effect of Coverage and Cost-of-Care Links, a program providing financial navigation, investigators initiated a nonrandomized study.

FDA Grants Fast Track Designation to Botensilimab Plus Balstilimab in Non–MSI-H/dMMR mCRC

April 20th 2023

The FDA has granted a fast track designation to the combination of botensilimab plus balstilimab for the treatment of patients with non–microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer with no active liver involvement.

IO-108 Demonstrates Safety and Efficacy in Advanced Solid Tumors

April 19th 2023

Findings from a phase 1 study showed that the fully humanized IgG4 antibody IO-108 was well tolerated and displayed durable responses when given as a monotherapy as well as in combination with pembrolizumab, supporting further development of the agent alone or with PD-1/PD-L1 targeted therapy for patients with advanced solid tumors.

FDA Approves Polatuzumab Vedotin Plus R-CHP for Previously Untreated DLBCL

April 19th 2023

The FDA has approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone for use in adult patients who have previously untreated diffuse large B-cell lymphoma, not otherwise specified or high-grade B-cell lymphoma and who have an International Prognostic Index score of two or greater.

Post-Hoc Analysis Supports Adjuvant Pembrolizumab in ccRCC at Increased Risk of Recurrence

April 19th 2023

Adjuvant pembrolizumab prolonged disease-free survival and distant metastasis–free survival vs placebo in patients with clear cell renal cell carcinoma at increased risk of recurrence after nephrectomy, irrespective of UCLA Integrated Staging System risk category and disease stage.

RLY-2608 Shows Broad Therapeutic Potential in PIK3CA-Mutant Solid Tumors

April 19th 2023

RLY-2608 led to sustained target inhibition with minimal effect on glucose homeostasis, acceptable safety, and antitumor activity in patients with PIK3CA-mutant solid tumors, according to interim data from the dose-escalation portion of the first-in-human phase 1 ReDiscover trial.

Cancer Center Lands Prestigious NCI Grant to Advance Immunotherapy in Head and Neck Cancer

April 19th 2023

April is Head and Neck Cancer Awareness Month, and a promising new research initiative at UC Davis Comprehensive Cancer Center could lead to a new and far more effective standard of care for this group of cancers.